Welcome to Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialise innovative products for unmet medical needs in psychiatry and neurology. We are developing six clinical-stage compounds acquired through strategic partnerships with Roche, Novartis and Syngenta. Our pipeline includes two marketed drugs that will be tested in new indications, extending their reach into new neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.

Pipeline

In 2008, we plan to start four phase II clinical trials informed by data from efficient proof-of-concept studies.

Source
preclinical
Phase 0
Phase I
Phase II
Phase III
Novartis Rufinamide
SYN-111
     
Phase II
 
Anxiety          
Roche A2a antagonist
SYN-115
     
Phase II
 
Parkinson's disease          
Syngenta Nitisinone
SYN-118
   
Phase I
   
Parkinson's disease          
Roche DBH inhibitor
SYN-117
   
Phase I
   
Drug dependency          
Roche 5-HT6 antagonist
SYN-114
   
Phase I
   
Cognitive disorders          
Roche IP inhibitor
SYN-116
   
Phase I
   
Acute pain          
Roche mGluR-1 agonist
SYN-119
Preclinical
       
Drug dependency          
Download Company Brochure PDF
get the fast facts on Synosia

Learn More
BioBusiness Network 2007 Award Winner

Scrip Awards 2007 Finalist
Finalist for Licensing Deal of the Year

Email registration

Sign up for regular updates
on Synosia.

Synosia Therapeutics adopts a privacy policy and will not disclose your email address or details to any third party.